Allergic rhinitis
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- Inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea, and itching. It may lead to fatigue, drowsiness, and malaise thus causing impairment of the quality of life.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Allergic rhinitis
- Therapeutic area
- Pulmonology
- allergic rhinitis
- allergic form of rhinitis
- allergic rhinitis
- Perenial allergic rhinitis
- atopic rhinitis
- non-seasonal allergic rhinitis
- perennial allergic rhinitis
- seasonal allergic rhinitis
- Disease mechanisms
- Inflammatory
- Severity
- Mild
- Immunology
- Pulmonology
- MONDO ID
- MONDO:0011786
- Parent condition
- MONDO:0000771
Related records
Broader conditions (16)
- Allergic disease
- Allergic respiratory disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Hypersensitivity reaction disease
- Immune system disorder
- Inflammatory disease
- Mucositis
- Nasal cavity disorder
- Nasal disorder
- Otorhinolaryngologic disease
- Respiratory system disorder
- Rhinitis
- Upper respiratory tract disorder
Narrower conditions (3)
- Perennial allergic rhinitis
- Seasonal allergic rhinitis
- Vasomotor rhinitis
Trials (677)
- "Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients"
- "Studio NaVA" - National Study on Quality of Life in Adolescents Affected by Allergic Rhinitis With or Without Asthma
- 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
- 3-D Visualization of the Anti-Obstructive Effect of Levocetirizine
- 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
- A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
- A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber
- A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
- A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
- A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy
- A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
- A Novel Biologic Therapy for Perennial Allergic Rhinitis
- A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects
- A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler
- A Phase 1 Study of Cizutamig in IgE Mediated Diseases
- A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL
- A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
- A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
Approved drugs (31)
- Atropine sulfate
- Azelastine hydrochloride
- Beclomethasone dipropionate
- Budesonide
- Cetirizine hydrochloride
- Chlorpheniramine maleate
- Ciclesonide
- Clemastine fumarate
- Desloratadine
- Dexamethasone
- Dexamethasone sodium phosphate
- Dexchlorpheniramine maleate
- Diphenhydramine hydrochloride
- Epinephrine
- Fexofenadine hydrochloride
- Fluticasone furoate
- Fluticasone propionate
- Loratadine
- Mometasone furoate
- Montelukast
Drugs in development (47)
- ADC3680 Phase 2
- AZD-8848 Phase 2
- Azelastine Phase 3
- Bamirastine Phase 2
- Betamethasone Phase 3
- Borneol Phase 2
- CAL-263 Phase 1
- Cetirizine Phase 3
- Doxylamine succinate Phase 1
- Dupilumab Phase 2
- Ensifentrine Phase 2
- Epinastine Phase 3
- Esketamine Phase 1
- Fevipiprant Phase 2
- Freneslerbart Phase 3
- Ginger Phase 2
- GSK-1004723 Phase 2
- GW-328267 Phase 1
- Histamine Phase 2
- HT-0712 Phase 2
Other linked drugs (26)
- Acrivastine
- Astemizole
- Azatadine
- Beclomethasone
- Bepotastine
- Bilastine
- Brompheniramine
- Chlorpheniramine
- Clemastine
- Cromolyn
- Diphenylpyraline
- Emedastine difumarate
- Epinastine hydrochloride
- Fexofenadine
- Flunisolide
- Fluticasone
- Isopropamide iodide
- Levocetirizine dihydrochloride
- Mequitazine
- Methacholine